Bajaj Healthcare's steady quarter, muddled peptide timeline
Q1 revenue up 11% but management's shifting guidance on the peptide plant erodes confidence in its ₹900-1,000 crore revenue target.
The numbers
- Standalone revenue from continuing ops at ₹165.63 cr, up 11% YoY.
- PBT rose to ₹16.46 cr from ₹14.53 cr, a 13% increase.
- Gross margin improved 210 bps to 48.3%; debt-equity improved to 0.5.
- Trailing P/E stands at 47.8, pricing in growth the quarter's figures don't justify.
Management's story
- Revenue target of ₹900-1,000 crore in 2-3 years, driven by peptide plant, oncology, and branded formulations.
- Peptide plant at full utilization could generate ₹200-300 cr at 18-20% margins.
- FY27-28 revenue growth guided at 10-15%; EBITDA margin 18-20%.
- Domestic API volume grew 27%; shift to higher-margin branded products.
“Our plant is going to commercialize in Q4 of this year. The first production would be Semaglutide.”
— Management, later in call
Where they diverge
The numbers show a steady quarter, but management's narrative is undermined by a glaring contradiction: the peptide plant is said to commission by Q4 2027, then earlier in Q4 of this fiscal year, then back to Q4 2027—all on the same call. Without a clear timeline, the ₹200-300 crore revenue potential from peptides remains a hope, not a forecast. Investors are left to guess which guidance to trust.
The full read
Bajaj Healthcare's Q1 was solid: revenue up 11%, PBT up 13%, gross margins expanding. But the call's timeline confusion casts doubt on its ambitious growth story. Management guided for ₹900-1,000 crore revenue in 2-3 years, anchored on a peptide plant that could add ₹200-300 crore at attractive margins. Yet on the same call, they gave three different dates for the plant's commissioning: Q4 2027, then Q4 of this fiscal year, then back to Q4 2027. No explanation was offered. For a stock trading at 47.8 times trailing earnings, investors are already paying for that future. The quarter's modest uptick doesn't support the premium. Until management provides a single, credible date for the peptide plant, the stock's multiple rests on faith, not facts.
What we're watching
- Peptide plant commissioning: management must clarify whether commercialization is Q4 FY27 or Q4 FY26.
- Cenobamate launch: expected ₹10-12 cr in FY27, pending regulatory approvals.
- Exports target of 30-35% of revenue; monitor quarterly export share.
- Gross margin trajectory: whether 18-20% EBITDA margin holds with receivables at 131 days.